Projected cost-effectiveness of pneumococcal conjugate vaccination of healthy infants and young children.
about
Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and pneumonia with consolidation on x-ray in children under two years of ageA human monoclonal immunoglobulin M reduces bacteremia and inflammation in a mouse model of systemic pneumococcal infectionPrioritization of influenza pandemic vaccination to minimize years of life lost.The health and economic impact of vaccination with 7-valent pneumococcal vaccine (PCV7) during an annual influenza epidemic and influenza pandemic in ChinaPublic health and economic impact of vaccination with 7-valent pneumococcal vaccine (PCV7) in the context of the annual influenza epidemic and a severe influenza pandemic.Impact of 13-valent pneumococcal conjugate vaccine (PCV13) in a pandemic similar to the 2009 H1N1 in the United StatesAntibiotic use in Thailand: quantifying impact on blood culture yield and estimates of pneumococcal bacteremia incidenceNew pneumococcal vaccines for children.Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.Too much of a good thing? When to stop catch-up vaccinationPneumococcal conjugate vaccination in Canadian infants and children younger than five years of age: Recommendations and expected benefits.Current state of pneumococcal vaccines.Conjugated heptavalent pneumococcal vaccine.New potential in pneumococcal immunization. Conjugate vaccine may improve disease protection, health of infants and young children.Modeling the impact of the 7-valent pneumococcal conjugate vaccine in Chinese infants: an economic analysis of a compulsory vaccination.Cost-effectiveness studies of pneumococcal conjugate vaccines.Epidemiological and economic burden of pneumococcal diseases in Canadian children.Estimating long-term clinical effectiveness and cost-effectiveness of HPV 16/18 vaccine in China.Nasopharyngeal colonization: a target for pneumococcal vaccination.The burden of pneumococcal disease in the Canadian population before routine use of the seven-valent pneumococcal conjugate vaccine.Economic evaluation of pediatric influenza immunization program compared with other pediatric immunization programs: A systematic review.Model for assessing human papillomavirus vaccination strategies.Cost-effectiveness analysis of infant universal routine pneumococcal vaccination in Malaysia and Hong Kong.Prevention and treatment of rheumatic heart disease in the developing world.Vaccination ecosystem health check: achieving impact today and sustainability for tomorrow.Pneumococcal conjugate vaccine: review of cost-effectiveness studies in Australia, North America and Europe.QALY weights for neurosensory impairments in pediatric economic evaluations: case studies and a critique.Cost effectiveness of pneumococcal conjugate vaccination against acute otitis media in children: a review.Cost-effectiveness models of pneumococcal conjugate vaccines: variability and impact of modeling assumptions.The costs and effectiveness of large Phase III pre-licensure vaccine clinical trials.Pneumococcal meningitis: clinical course and resource use in Western Australian children.Will genetic testing alter the management of disease caused by infectious agents? A cost-effectiveness analysis of gene-testing strategies for prevention of rheumatic Fever.Protein conjugate pneumococcal vaccines.New vaccines and the rising costs of caring.Guidelines for quality standards for immunization.Long-term outcomes of pneumococcal meningitis in childhood and adolescence.Simplifying rules for optimal allocation of preventive care resources.Population-based versus practice-based recall for childhood immunizations: a randomized controlled comparative effectiveness trial.Impact of PCV7 on invasive pneumococcal disease among children younger than 5 years: a population-based study
P2860
Q24245934-56E152AE-3A8F-4CE0-9E55-302864558C11Q24672825-D4DACA55-78A7-4A7E-A097-ED2A2D7EBBAEQ30370024-D7450588-0D1C-4FB4-9A8B-3EF5BEC04490Q30377116-18424944-F6F3-41BC-BB25-60FBC73121F5Q30384713-FEE8FD30-7209-4A8B-AAA5-4DDA54B17CBFQ30430741-71503BEF-D165-4A58-8089-686C82754FFAQ34024818-F140C854-F7B9-42D0-A1E9-FC8866A67270Q34190093-F4710233-64C4-476D-923A-5B84AAF9EF8EQ34578813-B98EA73D-DE14-4437-84BD-F03D03D7390BQ34585496-3EBFD12B-0E40-423B-87E8-3B34010A5425Q34590621-20268BA3-C4F0-47CC-9268-A52BEFC97539Q34744239-602513A6-91A1-409C-92E1-41D3B7D6AA28Q34796973-C3AB667C-0A8A-4CF8-B9C1-54E3C0877DF1Q35014547-6B2BEEE8-3885-4632-B16C-68F77356A87FQ35089126-E9BBA06A-A4AC-4861-9DDF-BDF645E18DBCQ35843639-0146F52F-776B-4506-B48D-4AAC2C6FE2D6Q36170777-B14010CE-3E7C-4DF5-8A62-8661C9554DC1Q36183172-979505D7-A4B1-4FA2-9944-418B029D0491Q36689018-2CA6AACA-9C7D-40FD-A9AA-406ED66EFD01Q36871048-44F56CB5-3C54-44B8-8EAE-0634F3DBD85DQ37131038-81BE3B89-8039-4FCD-A20A-38517FCFD34DQ37302509-3AFA7292-182F-4C04-B79B-CF86A5B47DB1Q37309195-97FFC72F-0F93-4D74-817C-675D58DCB1AEQ37596966-2484218A-5C92-4451-B82A-281DA45F9AB7Q37622789-4A163A5A-E77A-4DD4-96A8-73DAE5718506Q37763127-6A82C0F4-765B-4F8E-8934-4EDDFAFCB99FQ37764874-CFF2F62C-DA13-46A5-B7D7-4C003BF5460CQ37830688-27782570-B03D-4E7D-830E-7D6B41593716Q38061474-B71C07A7-0016-4FA7-A8D8-D64A11F397FCQ38594385-97C0F1C9-BA1B-4305-BBAD-BC8111A58474Q39697064-D4559D01-AD4C-4FA0-944D-CA19B896D7C0Q40582072-7188B589-E7F7-4AB8-9594-CD366E9B6BB0Q42776843-819EAF35-FE6A-4560-AE7B-990ADF2B4706Q42919221-E7982612-5C47-48BA-BAB5-E33BDB3CD0FBQ44691278-0DC0CF13-86E0-404B-A46A-58C01F4D2D47Q46062619-9C256EEC-B537-4D77-BF99-EEA3F2477335Q51393156-A21DF54B-26B8-4C79-8655-251CC633240BQ55686325-F95BA8D7-4514-4AAB-AAF6-A82051B82D19Q56894914-E207A2CC-9A13-49BE-B200-63590567AAA9
P2860
Projected cost-effectiveness of pneumococcal conjugate vaccination of healthy infants and young children.
description
2000 nî lūn-bûn
@nan
2000 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի մարտին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Projected cost-effectiveness o ...... hy infants and young children.
@ast
Projected cost-effectiveness o ...... hy infants and young children.
@en
type
label
Projected cost-effectiveness o ...... hy infants and young children.
@ast
Projected cost-effectiveness o ...... hy infants and young children.
@en
prefLabel
Projected cost-effectiveness o ...... hy infants and young children.
@ast
Projected cost-effectiveness o ...... hy infants and young children.
@en
P2093
P356
P1476
Projected cost-effectiveness o ...... hy infants and young children.
@en
P2093
H R Shinefield
J C Butler
M A Miller
R F Breiman
P304
P356
10.1001/JAMA.283.11.1460
P407
P577
2000-03-01T00:00:00Z